Keywords: novartis, wins, starlix, ok, switzerland, new, oral

Novartis wins Starlix OK in Switzerland

Article | 05 October 2000

Print This

Novartis' new oral drug for type 2 diabetes, Starlix (nateglinide),has been approved in Switzerland, its first European market. It is ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in